Showing 4031-4040 of 5646 results for "".
- Nidek and Hoya Vision Care Enter Global Partnershiphttps://modernod.com/news/nidek-and-hoya-vision-care-enter-global-partnership/2481381/Nidek has announced a partnership with Hoya Vision Care that would allow Hoya's customers access to Nidek's optical products, services and instruments through both local distributors. Financial terms of the deal were not disclosed. The aim of the partnership
- Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-6-month-results-from-oasis-extension-study-with-suprachoroidal-cls-ax-in-wet-amd/2481380/Clearside Biomedical announced positive results from the extension study of its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) parti
- Nidek Launches the AL-Scan M Optical Biometerhttps://modernod.com/news/nidek-launches-the-al-scan-m-optical-biometer/2481376/Nidek has announced the launch of the AL-Scan M Optical Biometer and the MV-1 Myopia Viewer software. The AL-Scan M incorporates 3D auto tracking and auto shot functions, designed for easy operation and quick measurement similar to an auto refractometer. Nidek says the features&nbs
- Dr. Reddy's Launches Generic Version of Durezol in the UShttps://modernod.com/news/dr-reddys-launches-generic-version-of-durezol-in-the-us/2481368/Following FDA approval, Dr. Reddy’s Laboratories announced the US launch of "Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%," a therapeutic generic equivalent to Durezol (Difluprednate Ophthalmic Emulsion 0.05%; Novartis), according to a company news release.
- TFS HealthScience Acquires Appletree CI Group, Expanding Presence in Ophthalmologyhttps://modernod.com/news/tfs-healthscience-acquires-appletree-ci-group-expanding-into-ophthalmology/2481363/Contract research organization TFS HealthScience announced it has acquired Appletree CI Group, a CRO and global regulatory affairs service provider. Terms of the deal were not disclosed. The deal enhances TFS HealthScience's presence in the fields of op
- Three-Month Efficacy/Safety Data of SING IMT for AMD Publishedhttps://modernod.com/news/three-month-efficacysafety-data-of-sing-imt-for-amd-published/2481362/The first and largest single-surgeon case series to describe the short-term (3 months) safety and efficacy outcomes of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in patients with severe to profound bilateral central vision impairment due to advanced A
- CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Boardhttps://modernod.com/news/cxl-ophthalmics-appoints-jonathan-talamo-md-as-chair-of-the-board/2481355/CXL Ophthalmics announced that Jonathan Talamo, MD, has been appointed as its new Chair of the Board of Directors. Dr. Talamo has served as a Board member for the company since 2020. CXLO is developing a minimally-invasive treatment for ectatic corneal disease. The company's Ep
- Bausch + Lomb Acquires AcuFocushttps://modernod.com/news/bausch-lomb-acquires-acufocus/2481353/Bausch + Lomb announced it has acquired AcuFocus, maker of the IC-8 Apthera IOL. Financial terms of the deal were not disclosed. The moves bolsters Bausch + Lomb's cataract surgery portfolio. AcuFocus' IC-8 was approved by the FDA in July
- CORE Names Its “Top 10 of 2022” Scientific Papershttps://modernod.com/news/core-names-its-top-10-of-2022-scientific-papers/2481351/Ahead of the first global eye care conference of the year, the Centre for Ocular Research & Education (CORE) has announced its “Top 10 of 2022” publications list, designating works of significant value to clinicians, researchers, educators, and manufacturers. The papers
- Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerabilityhttps://modernod.com/news/glaukos-announces-positive-results-for-idose-tr-exchange-trial-highlighting-favorable-safety-and-tolerability/2481346/Glaukos announced positive results for a prospective, multicenter clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the phase